DOI: 10.7759/cureus.33849

Review began 12/15/2022 Review ended 12/22/2022 Published 01/16/2023

© Copyright 2023

Alpagat et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

# Amoxicillin/Clavulanic Acid-Induced Symmetric Drug-Related Intertrigious and Flexural Exanthema

Gulistan Alpagat <sup>1</sup>, Ayse Baccioglu <sup>1</sup>, Betul Dumanoglu <sup>1</sup>, Sumeyra Alan Yalim <sup>1</sup>, Ayse Fusun Kalpaklioglu <sup>1</sup>

1. Department of Immunology and Allergic Diseases, Kirikkale University Faculty of Medicine, Kirikkale, TUR

Corresponding author: Gulistan Alpagat, gulistanalpagat16@gmail.com

#### **Abstract**

β-Lactams, particularly penicillins, may cause several allergic reactions. We described symmetric drug-related intertriginous and flexural exanthema (SDRIFE) illness in this case, a rare instance of systemic contact dermatitis caused by amoxicillin/clavulanic acid that needs to be considered in the differential diagnosis. A 65-year-old male patient was admitted to our Allergy Outpatient Clinic because of increased blue-purple pigmentation on the flexural surfaces of the hip, forearm, axilla, and posterior face of the neck. The patient was receiving a combination of angiotensin receptor blocker (ARB) and hydrochlorothiazide diuretic medication for hypertension. The patient used an antibiotic containing amoxicillin three months ago; As a result, there was localized redness, itching, and black spotting without any systemic symptoms. Similarly, the patient reported that when he used amoxicillin for an upper respiratory tract infection eight months ago, he experienced similar side effects within 20 days and recovered when he applied corticosteroid ointment.

Due to the symmetrical site involvement following the consumption of penicillin group antibiotics with a five-month gap and subsequent comparable reactions in our patient, SDRIFE was taken into consideration. The results of the skin punch biopsy identified Baboon Syndrome (SDRIFE). Treatment with topical corticosteroids and antihistamines began. Clinically speaking, SDRIFE is distinguished by significant erythema of the gluteal/perianal area and/or V-shaped erythema of the inguinal/perigenital area, symmetric involvement of at least one other intertriginous or flexural area, and the absence of systemic signs or symptoms. The possibility that the medication may have contributed to the patient's erythematous eruption in the flexural regions should be taken into account, and the patient should be advised to stop taking the medication and not use it again.

Categories: Dermatology, Allergy/Immunology

Keywords: anti-histamin, steroid treatment, amoxicilline, sdrife, drug-induced hypersensitivity

### Introduction

Different allergic reactions that are categorized as early or immediate and delayed type can be brought on by  $\beta$ -lactams. The most frequent allergic reactions to penicillin are maculopapular eruptions and urticaria. Even though maculopapular eruptions are the most common late-type reactions, there are some rare ones such as symmetrical drug-related intertriginous and flexural exanthema (SDRIFE). After exposure to systemic medications, this reaction manifests as a symmetrical erythematous rash on the gluteal and intertriginous areas. Since the location of the lesions on the buttocks and inner thighs mimics the red rump of baboons, SDRIFE is also known as "baboon syndrome"[1]. Regardless of antecedent sensitization, Hausermann et al. advocated the name SDRIFE as more suitable for reactions that happen following exposure to systemic medicines or local injection of contact allergens and pharmaceuticals [2]. Ceftriaxone, penicillin, and erythromycin were listed as the most frequent causes of SDRIFE [3]. Here, we describe a rare instance of SDRIFE who, upon treatment with amoxicillin and clavulanic acid, experienced a delayed reaction

#### **Case Presentation**

A 65-year-old man was referred to our Allergy Outpatient Clinic in with a rash that sprang out of nowhere, itching and burning in the flexural areas of the extremities, then becoming blue-purple. No overall symptoms existed. For five days, he took amoxicillin-clavulanic acid (875mg/125mg, twice a day) po with symptoms of upper airway infection. Although his symptoms subsided, 4-5 days after stopping the medicine, skin issues appeared. Eight months ago, he had experienced similar skin manifestations in a milder delayed reaction to the same drug. Since there was no definitive diagnosis at that time, the reaction was not thought to be drug-related. Skin lesions were partially resolved with topical corticosteroids, and brown spots remained. He had no previous history of contact with allergen administration.

Dermatological examination of the posterior neck and the intertriginous area revealed many bilateral, symmetrical, well-demarcated blue-purple macules and plaques involving the axillary, flexures of the

## **Cureus**

extremities, inguinal, and gluteal regions (Figure 1). In the form of pustules, papules, purpura or bullae. There were no skin lesions on the palms, soles, or mucosae. A systemic analysis turned out nothing unusual. Urinalysis results and blood cell counts were both normal. For a superficial fungal infection, direct microscopic inspection and culture produced negative results.




FIGURE 1: Skin exanthema of various sites due to SDRIFE (A: Flexural forearm, B: Axillar area, C: Posterior neck, C: Inguinal region).

Skin biopsy from the inguinal region was histopathologically examined, and the results were consistent with SDRIFE. They revealed focal parakeratosis of the epidermis, significant spongiosis, irregular acanthosis, and perivascular moderately mixed inflammation in the dermis (Figure 2). Based on histology and clinical characteristics, SDRIFE was defined (Figures 2, 3).




FIGURE 2: Perivascular inflammation

### Cureus




FIGURE 3: Parakeratozis and spongiosis

Based on histology and clinical characteristics, SDRIFE was defined. The medication was dissolved in distilled water and petrolatum with a 30% concentration before being used for the patch test [4]. After that, prick and intradermal tests with penicillin (DAP penicillin® (Diater laboratories, Madrid, Spain), penicillin G, and ampicillin/amoxicillin preparations) were performed and yielded negative. For prick testing, amoxicillin/clavulanic acid in tablet forms was mashed and diluted with 1 mL physiological saline solution. An intradermal test was not performed because of parenteral amoxicillin-clavulanic acid form is unavailable in Turkey. Although the gold standard test for drug allergy was a drug provocation test with the offending drug, this was not done because the patient had a broad reaction that had been getting worse over time [5]. With prednisolone (40 mg/day) for five days and p.o. anti-histamine for 20 days, his skin lesions significantly improved. It is recommended to avoid medications containing amoxicillin/clavulanic acid.

### **Discussion**

Here, we described an uncommon disorder called SDRIFE, a unique variation of eczematous skin diseases with a small number of documented instances. We hypothesize that the real prevalence of SDRIFE is likely higher than previously believed. According to clinical criteria, SDRIFE can be defined by the development of symmetrical, sharply delineated erythema on the buttocks and/or thighs after exposure to systemic medications, involvement of the flexural fold, and the absence of systemic symptoms [6]. With axillary regions localized, symmetrical eruptions, and no systemic symptoms, this patient satisfied all the criteria. Interestingly, despite the disease's name being derived from this participation, our patient's buttock regions were not affected. Although the cause of the lesions' usual placement in SDRIFE is unknown, it has been proposed that inflammation and blockage of sweating in these areas may be to blame [7]. When there has been prior sensitization, the site of the lesion is comparable to that of allergic contact dermatitis; however, when there has not been prior sensitization, the lesion takes the appearance of extensive eczematous plaques that have the propensity to coalesce [2].

Fixed drug eruption, acute generalized exanthematous pustulosis, and drug rash with eosinophilia and systemic symptoms are among the differential diagnoses. Lesions on the face and palmoplantar surfaces are not prevalent in SDRIFE, and neither are mucosal or systemic involvements at the time of presentation [8].

As in this case, SDRIFE lesions have maculopapular erythema with itching. Pustules, papules, blisters, purpuric lesions, and involvement of the palms, soles, face, or mucosae are uncommon atypical manifestations [8]. Given that our case was a man, which is consistent with the research, it is more common in men [9].

Since the pathophysiology can mirror acute generalized pustular dermatosis, bullous drug eruptions, lichenoid dermatitis, vasculitis, or dermatoses, the clinical diagnostic criteria are crucial. The reaction, which resembles a type IV delayed-type hypersensitivity immune reaction, typically manifests 1 to 14 days after the medicine was taken [2,10]. The most often reported drugs in SDRIFE include chemotherapeutic agents,

### Cureus

radio-contrast agents, non-steroidal anti-inflammatory drugs, anti-hypertensives, and anti-infective agents, particularly  $\beta$ -lactam antibiotics [2,9,11]. Drug challenge tests are not required [12]; however, they can be useful in identifying the offending substance. In our case, skin testing was unable to detect the culprit drug. However, a previous history of a similar reaction and the recurrence of the same skin lesions following the patient's second dose of amoxicillin/clavulanic acid can be regarded as signs of an unintentionally positive drug provocation test. Treatment for SDRIFE involves stopping the culprit drug and then using topical or systemic corticosteroids. After receiving treatment with oral corticosteroid (40 mg for 10 days) and antihistamine, as well as topical corticosteroid on the afflicted areas, our patient showed improvement.

# **Conclusions**

It is crucial to mention this unusual drug reaction because, unless the connection between the drug intake and the condition is not noted, it can be easily missed. This case was intriguing because it had an unusual diagnosis and no buttock skin eruptions. In situations of symmetrical intertriginous involvement and flexural exanthema, a thorough history must be collected due to the common usage of amoxicillin/clavulanic acid. Based on histology and clinical characteristics, SDRIFE was diagnosed, and also other diagnoses were excluded with a skin biopsy.

#### **Additional Information**

#### **Disclosures**

Human subjects: Consent was obtained or waived by all participants in this study. Kirikkale University Ethics Committee Decision on Non-Interventional Research issued approval 2021.02.04. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

#### References

- Andersen KE, Hjorth N, Menné T: The baboon syndrome: systemically-induced allergic contact dermatitis. Contact Dermatitis. 1984, 10:97-100. 10.1111/j.1600-0536.1984.tb00343.x
- Häusermann P, Harr T, Bircher AJ: Baboon syndrome resulting from systemic drugs: is there strife between SDRIFE and allergic contact dermatitis syndrome?. Contact Derm. 2004, 51:297-310. 10.1111/j.0105-1875.2004.00445.x
- Mofarrah R, Mofarrah R, Kränke B, et al.: First report of tamoxifen-induced baboon syndrome. J Cosmet Dermatol. 2021, 20:2574-8. 10.1111/jocd.13863
- Chongpison Y, Palapinyo S, Mongkolpathumrat P, Buranapraditkun S, Thantiworasit P, Klaewsongkram J:
   Beta-lactam hypersensitivity diagnosis in ambulatory and hospitalized settings require different
   approaches. Ann Allergy Asthma Immunol. 2022, 10.1016/j.anai.2022.09.011
- Romano A, Atanaskovic-Markovic M, Barbaud A, et al.: Towards a more precise diagnosis of hypersensitivity to beta-lactams - an EAACI position paper. Allergy. 2020, 75:1300-15. 10.1111/all.14122
- Mohapatra M, Panda M, Kar BR, Raj C: Symmetric drug-related intertriginous and flexural exanthema due to itraconazole: an un-common side effect of a commonly used drug. Indian Dermatol Online J. 2017, 8:501-3. 10.4103/idoi.IDOI 179 17
- Wolf R, Orion E, Matz H. 2003, 9:2.: The baboon syndrome or intertriginous drug eruption: a report of eleven cases and a second look at its pathomechanism. Dermatology online journal. 2003, 9:2. 10.5070/D36qk5r7nv
- 8. Tan SC, Tan JW: Symmetrical drug-related intertriginous and flexural exanthema . Curr Opin Allergy Clin Immunol. 2011, 11:313-8. 10.1097/ACI.0b013e3283489d5f
- Nespoulous L, Matei I, Charissoux A, Bédane C, Assikar S: Symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) associated with pristinamycin, secnidazole, and nefopam, with a review of the literature. Contact Dermatitis. 2018, 79:378-80. 10.1111/cod.13084
- Crowson AN, Brown TJ, Magro CM: Progress in the understanding of the pathology and pathogenesis of cutaneous drug eruptions: implications for management. Am J Clin Dermatol. 2003, 4:407-28.
  10.2165/00128071-200304060-00005
- Arnold AW, Hausermann P, Bach S, Bircher AJ: Recurrent flexural exanthema (SDRIFE or baboon syndrome) after administration of two different iodinated radio contrast media. Dermatology. 2007, 214:89-93. 10.1159/000096920
- Copaescu A, Gibson A, Li Y, Trubiano JA, Phillips EJ: An updated review of the diagnostic methods in delayed drug hypersensitivity. Front Pharmacol. 2020. 11:573573. 10.3389/fphar.2020.573573